Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease
CA 2821544 C · Owner: Paranta Biosciences Limited · Inventors: Fennessy, Paul; Phillips, David; Sievert, William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pharmaceutical compositions for the treatment and/or , prophylaxis of disease associated with fibrosis in a vertebrate said , composition comprising at , least one activin antagonist and optionally a pharmaceutically acceptable carrier, adjuvant , and/or diluents.. In selected embodiments the invention provides for the use , of follistatin in the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 12, 2002 and granted October 31, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 12, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 12, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.